Gastroenterology
Volume 139, Issue 2 , Pages 409-417, August 2010

Effects of Lesogaberan on Reflux and Lower Esophageal Sphincter Function in Patients With Gastroesophageal Reflux Disease

  • Guy E. Boeckxstaens

      Affiliations

    • Academic Medical Centre, Amsterdam, The Netherlands
    • Department of Gastroenterology, University Hospital Leuven, Catholic University of Leuven, Leuven, Belgium
    • Corresponding Author InformationReprint requests Address requests for reprints to: Guy E. Boeckxstaens, MD, Department of Gastroenterology, University Hospital Leuven, Catholic University of Leuven, Herestraat 49, 3000 Leuven, Belgium. fax: (32) 16 33 02 38
    • ,
  • Hanneke Beaumont

      Affiliations

    • Academic Medical Centre, Amsterdam, The Netherlands
    • ,
  • Veerle Mertens

      Affiliations

    • Department of Gastroenterology, University Hospital Leuven, Catholic University of Leuven, Leuven, Belgium
    • ,
  • Hans Denison

      Affiliations

    • AstraZeneca R&D, Mölndal, Sweden
    • ,
  • Magnus Ruth

      Affiliations

    • AstraZeneca R&D, Mölndal, Sweden
    • ,
  • John Adler

      Affiliations

    • AstraZeneca R&D, Mölndal, Sweden
    • ,
  • Debra G. Silberg

      Affiliations

    • AstraZeneca R&D, Wilmington, Deleware
    • ,
  • Daniel Sifrim

      Affiliations

    • Department of Gastroenterology, University Hospital Leuven, Catholic University of Leuven, Leuven, Belgium
    • Barts and The London School of Medicine and Dentistry, Queen Mary's College, University of London, London, United Kingdom

Received 15 February 2010; accepted 29 April 2010. published online 07 May 2010.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 30.00 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

 This article has an accompanying continuing medical education activity on page e16. Learning Objective: Upon completion of this exercise, successful learners will be able to describe key aspects of the mechanisms underlying gastroesophageal reflux disease and its treatment.

 Conflicts of interest The authors disclose the following: Dr Boeckxstaens has received an unrestricted grant, has participated in advisory boards of, and is/has been a consultant for AstraZeneca. Drs Denison, Ruth, Adler, and Silberg are employees of AstraZeneca. Dr Sifrim has received grant/research support from AstraZeneca. The remaining authors have no conflicts to disclose.

 Funding Supported by AstraZeneca R&D Mölndal, Sweden.

PII: S0016-5085(10)00659-1

doi:10.1053/j.gastro.2010.04.051

Gastroenterology
Volume 139, Issue 2 , Pages 409-417, August 2010

Article Tools

* Image Usage & Resolution